3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
9
NIH
2
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Arthritis, Rheumatoid
10
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Graft vs Host Disease
6
Leukemia
5
Breast Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
4
Lymphoma, Follicular
4
Leukemia, Myeloid, Acute
4
Myelodysplastic Syndromes
3
Lymphoma
3
Psoriasis
2
Neoplasms
2
Leukemia, Myeloid, Chronic-Phase
2
Leukemia, Myeloid, Accelerated Phase
2
Hematologic Neoplasms
2
Head and Neck Neoplasms
2
Carcinoma, Squamous Cell
2
Burkitt Lymphoma
2
Urinary Bladder Neoplasms
1
Stomatitis
1
Recurrence
1
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Osteosarcoma
1
Neutropenia
1
Mycosis Fungoides
1
Multiple Myeloma
1
Meningeal Neoplasms
1
Meningeal Carcinomatosis
1
Lymphoproliferative Disorders
1
Interventions
Temozolomide
29
Bevacizumab
14
Radiotherapy
12
Trastuzumab
10
Lomustine
9
Capecitabine
8
paclitaxel-Angiopep-2 conjugate
6
Nivolumab
6
pembrolizumab
5
dabrafenib
5
abemaciclib
5
Radiation
5
icotinib
4
Surgical Procedures, Operative
4
Paclitaxel
4
Lapatinib
4
Irinotecan
4
Flucytosine
4
Dianhydrogalactitol
4
Corticotropin-Releasing Hormone
4
Chlorotoxin
4
Carboplatin
4
vocimagene amiretrorepvec
3
verubulin
3
tucatinib
3
osimertinib
3
motexafin gadolinium
3
XL647
3
Spermine Synthase
3
Radiosurgery
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Brain Neoplasms
×
Methotrexate
×
Clear all
NCT03613181
2023-04-24
ANGLeD
Angiochem Inc
Phase 3
Unknown
150 enrolled